Dermira, Inc. (DERM) Lowered to “Sell” at Zacks Investment Research
Zacks Investment Research lowered shares of Dermira, Inc. (NASDAQ:DERM) from a hold rating to a sell rating in a research report released on Thursday morning.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
Other analysts have also recently issued reports about the company. Cantor Fitzgerald reaffirmed a buy rating and set a $45.00 price objective on shares of Dermira in a report on Monday, November 6th. Needham & Company LLC reaffirmed a buy rating and set a $46.00 price objective on shares of Dermira in a report on Sunday, September 17th. Mizuho reaffirmed a buy rating and set a $43.00 price objective (up from $40.00) on shares of Dermira in a report on Thursday, September 7th. Leerink Swann reaffirmed an outperform rating and set a $41.00 price objective (down from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Finally, BidaskClub cut Dermira from a hold rating to a sell rating in a report on Wednesday, August 2nd. Five investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $43.33.
COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/12/dermira-inc-derm-lowered-to-sell-at-zacks-investment-research.html.
In related news, CEO Thomas G. Wiggans sold 9,500 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $27.51, for a total transaction of $261,345.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $27.52, for a total value of $137,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 29,400 shares of company stock worth $822,553 in the last 90 days. 13.30% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its holdings in Dermira by 2,220.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 3,975 shares during the period. Quantbot Technologies LP raised its holdings in Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 2,309 shares during the period. SG Americas Securities LLC raised its holdings in Dermira by 66.8% during the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,203 shares during the period. KCG Holdings Inc. purchased a new stake in Dermira during the 1st quarter valued at $215,000. Finally, Legal & General Group Plc raised its holdings in Dermira by 16.3% during the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 963 shares during the period. Institutional investors own 97.89% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.